The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Gefitinib Accord 250 mg film coated tablets

250 milligram(s) Film-coated tablet

Accord Healthcare Ireland Ltd.PA2315/221/001

Main Information

Trade NameGefitinib Accord 250 mg film coated tablets
Active SubstancesGefitinib
Strength250 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderAccord Healthcare Ireland Ltd.
Licence NumberPA2315/221/001

Group Information

ATC CodeL01XE Protein kinase inhibitors
L01XE02 gefitinib

Status

Authorised/WithdrawnAuthorised
Licence Issued17/01/2020
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back